Ixekizumab met psoriasis endpoints by week 12, with durable response at 60 weeks
09/04/2015 - 15:18
SAN FRANCISCO – More than 80% of psoriasis patients who received ixekizumab achieved a 75% reduction in the Psoriasis Area and Severity Index score ... More »
